CVRx (CVRX) Resumen de Acciones
CVRx, Inc. es una empresa de dispositivos médicos en fase comercial que se dedica a desarrollar, fabricar y comercializar soluciones de neuromodulación para pacientes con enfermedades cardiovasculares en Estados Unidos, Alemania y otros países. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 3/6 |
| Crecimiento futuro | 1/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 5/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
CVRX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de CVRx, Inc.
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$6.06 |
| Máximo en las últimas 52 semanas | US$11.30 |
| Mínimo de 52 semanas | US$4.37 |
| Beta | 0.87 |
| Cambio en 1 mes | -16.30% |
| Variación en 3 meses | 14.77% |
| Cambio de 1 año | -3.19% |
| Variación en 3 años | -54.61% |
| Variación en 5 años | n/a |
| Variación desde la OPV | -78.36% |
Noticias y actualizaciones recientes
Artículo de análisis • May 15
The CVRx, Inc. (NASDAQ:CVRX) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Shareholders in CVRx, Inc. ( NASDAQ:CVRX ) had a terrible week, as shares crashed 22% to US$5.74 in the week since its...
Actualización de narrativa • May 05
CVRX: Reduced Multiple Expectations Will Likely Constrain Future Share Price Upside
Analysts have reduced their average CVRx price target by $1 to reflect updated views on the company’s risk profile, growth trajectory, profitability expectations, and likely P/E multiple, while keeping fair value broadly in line with prior estimates. Analyst Commentary Recent Street research on CVRx points to a more cautious tone, with the headline takeaways centered on slightly lower price targets and an increased focus on execution and valuation risks.Recent updates
Artículo de análisis • May 15
The CVRx, Inc. (NASDAQ:CVRX) First-Quarter Results Are Out And Analysts Have Published New Forecasts
Shareholders in CVRx, Inc. ( NASDAQ:CVRX ) had a terrible week, as shares crashed 22% to US$5.74 in the week since its...Actualización de narrativa • May 05
CVRX: Reduced Multiple Expectations Will Likely Constrain Future Share Price Upside
Analysts have reduced their average CVRx price target by $1 to reflect updated views on the company’s risk profile, growth trajectory, profitability expectations, and likely P/E multiple, while keeping fair value broadly in line with prior estimates. Analyst Commentary Recent Street research on CVRx points to a more cautious tone, with the headline takeaways centered on slightly lower price targets and an increased focus on execution and valuation risks.Actualización de narrativa • Apr 19
CVRX: Execution Risks And Updated Assumptions Will Likely Restrain Upside
Analysts have trimmed their price targets on CVRx by $1, citing updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. Analyst Commentary Recent research notes, including one from JPMorgan, point to a more cautious stance on CVRx, reflected in the $1 price target trims.Actualización de narrativa • Mar 31
CVRX: Execution Risks And Recent Price Cuts Will Likely Limit Upside
Analysts have trimmed their CVRx price targets by $1 to reflect updated assumptions around discount rates, revenue growth, profit margins, and future P/E expectations, while maintaining their fair value estimate at $6.00. Analyst Commentary Recent Street research, including updated work from JPMorgan, reflects a more cautious stance on CVRx even as the published fair value estimate remains at $6.00.Actualización de narrativa • Mar 16
CVRX: Execution Risks Around Profitability Path Will Likely Cap Future Upside
Analysts have trimmed their CVRx price targets by $1 to $6, reflecting updated assumptions around revenue growth, discount rate, profit margins, and future P/E expectations. Analyst Commentary Recent research updates point to a more cautious stance on CVRx, with both JPMorgan and other bearish analysts trimming price targets by $1.Actualización de narrativa • Mar 01
CVRX: Reimbursement Progress Will Face Cautious Outlook On Profitability Path
Analysts have trimmed their price target on CVRx by $1, reflecting updated assumptions around discount rates, revenue growth, profit margins and forward P/E that still align with recent Street research from firms that reduced their targets by a similar amount. Analyst Commentary Street research on CVRx has recently centered on slightly lower price targets, including a US$1 trim from JPMorgan, which aligns with similar reductions from other bearish analysts.Artículo de análisis • Feb 15
Analysts Are Updating Their CVRx, Inc. (NASDAQ:CVRX) Estimates After Its Full-Year Results
One of the biggest stories of last week was how CVRx, Inc. ( NASDAQ:CVRX ) shares plunged 24% in the week since its...Actualización de narrativa • Feb 15
CVRX: Reimbursement Shift And BENEFIT-HF Trial Will Reshape Long-Term Upside
Analysts have trimmed their CVRx price targets by $1, reflecting updated fair value estimates and assumptions on growth, profitability, and future P/E multiples, while maintaining a constructive view on the story. Analyst Commentary Recent Street research includes price target trims of $1 from both JPMorgan and other bearish analysts, which reflect a more cautious stance on CVRx's risk and reward profile.Artículo de análisis • Dec 30
CVRx, Inc.'s (NASDAQ:CVRX) Popularity With Investors Under Threat As Stock Sinks 26%
CVRx, Inc. ( NASDAQ:CVRX ) shareholders won't be pleased to see that the share price has had a very rough month...Artículo de análisis • Nov 08
CVRx, Inc. (NASDAQ:CVRX) Released Earnings Last Week And Analysts Lifted Their Price Target To US$11.50
CVRx, Inc. ( NASDAQ:CVRX ) just released its quarterly report and things are looking bullish. CVRx beat expectations...Artículo de análisis • Oct 16
After Leaping 39% CVRx, Inc. (NASDAQ:CVRX) Shares Are Not Flying Under The Radar
CVRx, Inc. ( NASDAQ:CVRX ) shares have had a really impressive month, gaining 39% after a shaky period beforehand...Artículo de análisis • Sep 16
Does CVRx (NASDAQ:CVRX) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Artículo de análisis • Aug 08
Analyst Estimates: Here's What Brokers Think Of CVRx, Inc. (NASDAQ:CVRX) After Its Second-Quarter Report
It's been a sad week for CVRx, Inc. ( NASDAQ:CVRX ), who've watched their investment drop 13% to US$6.94 in the week...Artículo de análisis • Jul 15
CVRx, Inc.'s (NASDAQ:CVRX) P/S Is Still On The Mark Following 25% Share Price Bounce
CVRx, Inc. ( NASDAQ:CVRX ) shareholders would be excited to see that the share price has had a great month, posting a...Seeking Alpha • Jul 02
CVRx: Sell-Off Ignores Its True Potential
Summary CVRx offers a unique, FDA-approved heart failure therapy with Medicare reimbursement, positioning it for significant market adoption and growth. The recent share price drop is an overreaction to sales force restructuring and reimbursement fears, while earnings and revenue estimates remain stable. Current valuation is deeply discounted versus sector peers, despite high-teens revenue growth and clear operating leverage potential as sales ramp up. Management insider buying and a net cash balance sheet reinforce my conviction that CVRX is a speculative Buy at these levels. Read the full article on Seeking AlphaArtículo de análisis • Jun 14
Is CVRx (NASDAQ:CVRX) Weighed On By Its Debt Load?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Artículo de análisis • May 09
Investors Appear Satisfied With CVRx, Inc.'s (NASDAQ:CVRX) Prospects As Shares Rocket 25%
Those holding CVRx, Inc. ( NASDAQ:CVRX ) shares would be relieved that the share price has rebounded 25% in the last...Seeking Alpha • Apr 09
CVRx, Inc.: Overreaction Creates Buying Opportunity
Summary CVRx, Inc. stock has recently dropped 40%, presenting a buying opportunity as the long-term growth potential remains intact. Barostim has strong clinical results and significant market potential, with a $2.2 billion TAM. Average selling prices can potentially improve as the market recognizes Barostim's effectiveness. CVRX shares are a buy with a price target of $10. Read the full article on Seeking Alpha
Nueva narrativa • Mar 29
Expanding 48 US Territories And New Codes Will Broaden Access
Expansion in US territories and implanting centers is expected to drive significant revenue growth and market penetration.Artículo de análisis • Mar 07
With A 29% Price Drop For CVRx, Inc. (NASDAQ:CVRX) You'll Still Get What You Pay For
CVRx, Inc. ( NASDAQ:CVRX ) shares have had a horrible month, losing 29% after a relatively good period beforehand...Artículo de análisis • Jan 16
Revenues Tell The Story For CVRx, Inc. (NASDAQ:CVRX) As Its Stock Soars 27%
Despite an already strong run, CVRx, Inc. ( NASDAQ:CVRX ) shares have been powering on, with a gain of 27% in the last...Artículo de análisis • Dec 26
Does CVRx (NASDAQ:CVRX) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Seeking Alpha • Nov 07
CVRx: Impressive Top-Line Growth Seems Priced In
Summary CVRx's Barostim therapy shows strong clinical success and impressive revenue growth. Recent reimbursement approvals from CMS enhance Barostim's sales potential. Despite double-digit sales growth and a promising product, CVRx's path to profitability is hindered by escalating SG&A costs and potential future shareholder dilution. CVRX is a hold with a price target of $14. Read the full article on Seeking AlphaArtículo de análisis • Nov 01
Analyst Estimates: Here's What Brokers Think Of CVRx, Inc. (NASDAQ:CVRX) After Its Third-Quarter Report
The investors in CVRx, Inc. 's ( NASDAQ:CVRX ) will be rubbing their hands together with glee today, after the share...Artículo de análisis • Oct 10
Investors Still Waiting For A Pull Back In CVRx, Inc. (NASDAQ:CVRX)
When you see that almost half of the companies in the Medical Equipment industry in the United States have...Artículo de análisis • Jul 31
Does CVRx (NASDAQ:CVRX) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Artículo de análisis • Jun 18
Why Investors Shouldn't Be Surprised By CVRx, Inc.'s (NASDAQ:CVRX) 32% Share Price Surge
Those holding CVRx, Inc. ( NASDAQ:CVRX ) shares would be relieved that the share price has rebounded 32% in the last...Artículo de análisis • May 04
The Price Is Right For CVRx, Inc. (NASDAQ:CVRX) Even After Diving 47%
To the annoyance of some shareholders, CVRx, Inc. ( NASDAQ:CVRX ) shares are down a considerable 47% in the last month...Artículo de análisis • Apr 10
Rock star Growth Puts CVRx (NASDAQ:CVRX) In A Position To Use Debt
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Artículo de análisis • Feb 29
The Price Is Right For CVRx, Inc. (NASDAQ:CVRX) Even After Diving 25%
CVRx, Inc. ( NASDAQ:CVRX ) shareholders won't be pleased to see that the share price has had a very rough month...Artículo de análisis • Nov 11
Revenues Tell The Story For CVRx, Inc. (NASDAQ:CVRX) As Its Stock Soars 34%
CVRx, Inc. ( NASDAQ:CVRX ) shareholders are no doubt pleased to see that the share price has bounced 34% in the last...Rentabilidad de los accionistas
| CVRX | US Medical Equipment | Mercado US | |
|---|---|---|---|
| 7D | 16.1% | 4.0% | -0.3% |
| 1Y | -3.2% | -18.6% | 26.7% |
Rentabilidad vs. Industria: CVRX superó a la industria US Medical Equipment, que obtuvo un rendimiento del -18.6% el año pasado.
Rentabilidad vs. Mercado: CVRX obtuvo unos resultados inferiores a los del mercado US, que fueron del 26.7% el año pasado.
Volatilidad de los precios
| CVRX volatility | |
|---|---|
| CVRX Average Weekly Movement | 12.5% |
| Medical Equipment Industry Average Movement | 8.6% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: El precio de las acciones de CVRX ha sido volátil durante los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de CVRX(12%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de US.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2000 | 223 | Kevin Hykes | www.cvrx.com |
CVRx, Inc. es una empresa de dispositivos médicos en fase comercial que se dedica a desarrollar, fabricar y comercializar soluciones de neuromodulación para pacientes con enfermedades cardiovasculares en Estados Unidos, Alemania y otros países. La empresa ofrece Barostim, un dispositivo implantable que envía impulsos eléctricos a los barorreceptores situados en la pared de la arteria carótida para contrarrestar la disminución de la señalización barorreceptora, y proporciona terapia de activación barorrefleja, que vincula el sistema cardiovascular con el sistema nervioso autónomo. Vende sus productos a través de una fuerza de ventas directa, agentes de ventas y distribuidores independientes.
Resumen de fundamentos de CVRx, Inc.
| Estadísticas fundamentales de CVRX | |
|---|---|
| Capitalización bursátil | US$159.48m |
| Beneficios(TTM) | -US$52.66m |
| Ingresos (TTM) | US$59.07m |
2.7x
Ratio precio-ventas (PS)-3.1x
Ratio precio-beneficio (PE)¿Está CVRX sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de CVRX | |
|---|---|
| Ingresos | US$59.07m |
| Coste de los ingresos | US$8.16m |
| Beneficio bruto | US$50.91m |
| Otros gastos | US$103.57m |
| Beneficios | -US$52.66m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -1.98 |
| Margen bruto | 86.18% |
| Margen de beneficio neto | -89.15% |
| Ratio deuda/patrimonio | 200.9% |
¿Cómo se ha desempeñado CVRX a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/20 11:53 |
| Precio de las acciones al final del día | 2026/05/20 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
CVRx, Inc. está cubierta por 9 analistas. 7 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| William Plovanic | Canaccord Genuity |
| Ross Osborn | Cantor Fitzgerald & Co. |
| Sarah James | Cantor Fitzgerald & Co. |